U.S. markets closed

PainReform Ltd. (PRFX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.5600+0.0500 (+1.11%)
At close: 3:59PM EST

PainReform Ltd.

60C Medinat Hayehudim Street
Herzliya 4676670
972 9 960 1901

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Ehud Geller Ph.D.Exec. Chairman & Acting CFON/AN/AN/A
Mr. Ilan Hadar M.B.A., MBAChief Exec. OfficerN/AN/A1969
Dr. David E. WeinsteinPres & Chief Medical OfficerN/AN/A1958
Dr. Sigal AvielChief Operating OfficerN/AN/A1964
Prof. Eli Hazum Ph.D.CTO & DirectorN/AN/AN/A
Dr. Stephen A. Cooper D.M.D Ph.D.Exec. VP of Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.

Corporate Governance

PainReform Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.